Real-world cost-effectiveness of rivaroxaban compared with vitamin K antagonists in the context of stroke prevention in atrial fibrillation in France.

Real-world cost-effectiveness of rivaroxaban compared with vitamin K antagonists in the context of stroke prevention in atrial fibrillation in France.

OBJECTIVE:The objective was to assess the real-world cost-effectiveness of rivaroxaban, versus vitamin K antagonists (VKAs), for stroke prevention in patients with atrial fibrillation (AF) from a French national health insurance perspective. METHODS:A Markov model was developed with a lifetime horiz...

Full description

Bibliographic Details
Main Authors: Kevin Bowrin, Jean-Baptiste Briere, Laurent Fauchier, Craig Coleman, Aurélie Millier, Mondher Toumi, Emilie Clay, Pierre Levy
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2020-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0225301

Similar Items

Similar Items